Business Description
Acumen Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US00509G2093
Total Employee Number:
61Description
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.12 | |||||
Equity-to-Asset | 0.66 | |||||
Debt-to-Equity | 0.36 | |||||
Debt-to-EBITDA | -0.29 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -22.5 | |||||
3-Year EPS without NRI Growth Rate | -23.4 | |||||
3-Year FCF Growth Rate | -29.9 | |||||
3-Year Book Growth Rate | -36.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 25.08 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 52.42 | |||||
9-Day RSI | 55.51 | |||||
14-Day RSI | 55.31 | |||||
3-1 Month Momentum % | -5.58 | |||||
6-1 Month Momentum % | 36.99 | |||||
12-1 Month Momentum % | 69.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.55 | |||||
Quick Ratio | 4.55 | |||||
Cash Ratio | 4.39 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13.9 | |||||
Shareholder Yield % | -19.92 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -108.15 | |||||
ROA % | -73.08 | |||||
ROIC % | -457.09 | |||||
3-Year ROIIC % | 1651.16 | |||||
ROC (Joel Greenblatt) % | -37954.74 | |||||
ROCE % | -83.89 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.18 | |||||
Price-to-Tangible-Book | 2.18 | |||||
EV-to-EBIT | -0.86 | |||||
EV-to-Forward-EBIT | -0.13 | |||||
EV-to-EBITDA | -0.86 | |||||
EV-to-Forward-EBITDA | -0.13 | |||||
EV-to-FCF | -0.89 | |||||
| Price-to-Net-Current-Asset-Value | 2.2 | |||||
| Price-to-Net-Cash | 2.32 | |||||
Earnings Yield (Greenblatt) % | -116.28 | |||||
FCF Yield % | -55.36 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ABOS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Acumen Pharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.86 | ||
| Beta | 2.8579 | ||
| 3-Year Sharpe Ratio | 0.15 | ||
| 3-Year Sortino Ratio | 0.24 | ||
| Volatility % | 58.46 | ||
| 14-Day RSI | 55.31 | ||
| 14-Day ATR ($) | 0.173484 | ||
| 20-Day SMA ($) | 2.4955 | ||
| 12-1 Month Momentum % | 69.29 | ||
| 52-Week Range ($) | 1.1901 - 3.6 | ||
| Shares Outstanding (Mil) | 72.23 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Acumen Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Acumen Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-12 08:00 | In 122 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 121 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-12 08:00 | In 30 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 29 days | ||
| General meeting for 2026 | 2026-06-03 11:00 | 2.37 (-5.58%) | ||
| Guidance call for 2026 | 2026-05-14 08:55 | 2.49 (+0.40%) | ||
| First quarter earnings conference call for 2026 | 2026-05-12 08:00 | 2.57 (+1.18%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 2.57 (+1.18%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-26 08:00 | 2.63 (-1.13%) | ||
| Annual report for 2025 | 2026-03-26 | 2.63 (-1.13%) |
Show
Entries
Acumen Pharmaceuticals Inc Frequently Asked Questions
What is Acumen Pharmaceuticals Inc(ABOS)'s stock price today?
The current price of ABOS is $2.64. The 52 week high of ABOS is $3.60 and 52 week low is $1.19.
When is next earnings date of Acumen Pharmaceuticals Inc(ABOS)?
The next earnings date of Acumen Pharmaceuticals Inc(ABOS) is 2026-08-12 Est..
Does Acumen Pharmaceuticals Inc(ABOS) pay dividends? If so, how much?
Acumen Pharmaceuticals Inc(ABOS) does not pay dividend.
Guru Commentaries on NAS:ABOS
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Thinking about buying stock in AMC Entertainment, Archer Aviation, Theseus Pharmaceuticals, Quantumscape, or Acumen Pharmaceuticals? | 2023-07-17 |
Articles on Acumen Pharmaceuticals Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers